GlassScriptPhysician profile
David G Ng
NPI 1558484618
$11,181.93
in general payments reported to CMS, 2019-2025
53 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $912 · 2021: $2,466 · 2022: $2,015 · 2023: $1,459 · 2024: $1,592 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,792 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,791.51 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,723.44 | 2019-2022 | |
| Amgen INC. | $1,178.83 | 2021-2025 | Repatha, Tezspire, Repatha |
| Astrazeneca Pharmaceuticals LP | $877.32 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $857.89 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Novartis Pharmaceuticals Corporation | $631.97 | 2022-2025 | |
| Insmed, INC. | $321.78 | 2024-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $318.98 | 2019-2024 | Yupelri |
| Collegium Pharmaceutical, INC. | $286.73 | 2024-2025 | Belbuca, Xtampza |
| Pfizer INC. | $285.41 | 2020-2025 | |
| Edwards Lifesciences Corporation | $262.40 | 2020-2025 | Sapien 3 Ultra Resilia |
| Pulmonx Corporation | $241.28 | 2020-2022 | |
| Glaxosmithkline, LLC. | $238.79 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $229.02 | 2019-2022 | |
| Verona Pharma, INC. | $219.96 | 2025 | Ohtuvayre |
| Novo Nordisk INC | $201.59 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.